Adjuvant radiochemotherapy for gastric cancer: Should we use prognostic factors to select patients?

Table 1 Characteristics and outcomes of principal phase III randomized trials that compared radiotherapy associated to chemotherapy or chemotherapy in patients affected by gastric cancer

Trial	Year	Surgery (node resection)	Locally advanced	Randomization scheme	RT dose	RT technique	Median FU	OS	DFS, PFS	Limits
SWOG/INT-0116[6]	2001	D1 90%	85%	S-alone vs S + CRT	45 Gy	2D	60 mo	3-yr: 50% vs 41% (P = 0.005)	3-yr: 48% vs 31% (P < 0.001)	Low rates of D2 node dissection
		D2 10%
MAGIC[8]	2006	D1 35%	71%	S-alone vs CT + S + CT	-	-	49 mo	5-yr: 23% vs 36% (P = 0.009)	3-yr: 26% vs 38% (P < 0.001)	Low adherence to post-operative CT
		D2 77%
NCC, South Korea[19]	2012	D2 100%	98%	S + CT vs S + CRT	45 Gy	2D/3D	87 mo	5-yr: 65% vs 55% (P > 0.05)	5-yr: 61% vs 50% (P > 0.05)	Poor accrual
ARTIST[7]	2012	D2 100%	86%	S + CT + CRT + CT vs S + CT	45 Gy	2D/3D	53 mo	NR	3-yr: 78% vs 74% (P = 0.086)	Planned events not reached

RT: Radiotherapy; FU: Follow up; OS: Overall survival; DFS: Disease-free survival; PFS: Progression-free survival; S: Surgery; CT: Chemotherapy; CRT: Chemoradiotherapy; 2D: 2-dimensional; 3D: 3-dimensional; NR: Not reported.